This study investigated the effects of continuous slow intravenous infusion of cholecystokinin
tetrapeptide (CCK-4) on brain stem auditory evoked potentials (BSAEP) in healthy subjects.
Twenty-four subjects, 15 females and 9males, were assigned to infusion with either
placebo or CCK-4 in a randomized, double-blind, parallel group design. BSAEPs, mood,
physical symptoms, and vital signs were assessed once before infusion and at 10 min
and 40 min after the onset of infusion. In the 16 subjects (N = 8, CCK-4; N = 8, placebo)
CCK-4, compared to placebo, delayed peak I latency during early infusion, slowed the
latencies of peaks III and V, and decreased the amplitude of peak III throughout the
infusion. No significant treatment differences were observed with respect to symptoms,
mood, or cardiovascular measures. These preliminary findings suggest that CCK-4 may
interfere with information processing in the brain stem auditory pathways and that
prolonged intravenous CCK-4 administration may be a useful challenge paradigm for
investigating CCK’s modulatory role on brain stem mechanisms mediating anxiety and
panic in humans.
Key words
Cholecystokinin - CCK-4 - brain stem auditory evoked potentials - anxiety, panic
References
- 1
Abelson J L, Nesse R M.
Pentagastrin infusions in patients with panic disorder. I: Symptoms and cardiovascular
responses.
Biol Psychiatry.
1994;
36
73-83
- 2
Albus M.
Cholecystokinin.
Prog Neuro-Psychopharmacol and Biol Psychiatry.
1988;
12
S5-21
- 3 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth
Edition ed Washington, D.C; American Psychiatric Association 1994
- 4
Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M.
The raphe nuclei of the cat brainstem: a topographical atlast of their efferent projections
as revealed by autoradiography.
Brain Res.
1976;
113
449-486
- 5
Bourin M, Malinge M, Guitton B.
Provocative agents in panic disorder.
Therapie.
1995;
50
301-306
- 6
Bradweyn J, Kosycki D, Meterissian G.
Cholccystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
Can J Psychiatry.
1990;
35
83-85
- 7
Bradwejn J, Koszycki D, Bourin M.
Dose ranging study of the effects of cholecystokinin in healthy volunteers.
J Psychiatry Neurosci.
1991;
16
91-95
- 8 Bradwejn J, Koszycki D, Payeur R. Cholecystokinin-tetrapeptide: A provocation agent
for research in panic disorders?. In Briley M, Files S (eds)
New Concepts in anxiety. MacMillan Press London; 1991
- 9
Bradwejn J, Koszycki D, Shriqui C.
Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder.
Arch Gen Psychiatry.
1991;
7
603-610
- 10 Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. In
Reeve JR Jr, Solomon TE, Go VL (eds)
Cholecystokinin. The New York Academy of Sciences New York, NY; 1994
- 11
Branchereau R, Champagnat J, Roques B, Denavit-Saubie M.
CCK modulates inhibitory synaptic transmission in the solitary complex through CCK
B sites.
Neuroeport.
1992;
3
909-912
- 12
Caspary D, Havey D, Faingold C.
Effects of microiontophoretically applied glycine and GABA on neuronal response pattern
in the cochlear nuclei.
Brain Res.
1979;
172
179-185
- 13
Charney D S, Heninger G R, Jatlow P.
Increased anxiogenic effects of caffeine in panic disorders.
Arch Gen Psychiatry.
1985;
42
233-243
- 14
Charney D S, Woods S W, Goodman W K, Heninger G R.
Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates
of yohimbine-induced panic attacks.
Am J Psychiatry.
1987;
144
1030-1036
- 15
Charney D S, Woods S W, Krystal J H, Nagy L M, Heninger G R.
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous
yohimbine and clonidine in panic disorder patients.
Acta Psychiat Scand.
1992;
86
273-282
- 16 Chiappa K. Evoked potentials in clinical medicine, Lippincott - Raven Publishers
(3rd Ed). Philadelphia; 1997
- 17
Coplan J D, Lydiard R B.
Brain circuits in panic disorder.
Biol Psychiatry.
1998;
44
1264-1276
- 18
Crawley J N, Corwin R L.
Biological actions of cholecystokinin.
Peptides.
1994;
15
731-755
- 19 Crawley J N. Interactions between cholecystokinin and other neurotransmitter systems. In
Bradwejn J, Vasar E (eds)
Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
- 20
de Montigny C.
Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers.
Arch Gen Psychiatry.
1989;
46
511-517
- 21 Derogatis L, Lipman R, Richels K. The Hopkins Symptom Checklist (HSCL): a measure
of primary symptom dimensions. In Pichot P (ed)
Psychological measurement: modern problems in pharmacopsychiatry. Karger Basel, Switzerland; 1979
- 22
Don M, Eggermont J.
Analysis of the click-evoked brainstem potentials in man using high-pass noise masking.
J Accost Soc Am.
1978;
63
1084-1092
- 23
Epstein C M.
The use of brain stem auditory evoked potentials in the evaluation of the central
nervous system.
Neurol Clin.
1998;
6
771-790
- 24
Eybalin M, Parnaud C, Geffard M, Pujoi R.
Immunoclectron miscroscopy identiifes several types of GABA- contaning efferent synapses
in the guinea-pig organ of Corti.
Neurosci.
1988;
24
29-38
- 25
Fex J, Altschuler R, Kachar B, Wenthold R, Zempel J.
GABA visualized by immunocytochemistry in the guinea pig cochlea in axons and endings
of efferent neurons.
Brain Res.
1986;
366
106-117
- 26
Fitzgerald J D.
Pentagastrin as a stimulant of maximal gastric acid response in man.
Lancet.
1967;
1(7485)
291-295
- 27
Gorman J M, Liebowitz M R, Fyer A J, Stein J.
A neuroanatomical hypothesis for panic disorder.
Am J of Psychiatry.
1989;
146
148-161
- 28
Harro J, Vasar E, Bradwejn J.
CCK in animal and human research on anxiety.
Trends Pharmacol Sci.
1993;
14
244-249
- 29
Harro J, Vasar E, Koszycki D, Bradwejn J.
Cholecystokinin in panic and anxiety disorders.
Adv Biol Psychiatry.
1995;
1
235-262
- 30
Hendry S, Jones E, DeFelipe J, Schmochel D, Brandon C, Emson P.
Neuropeptide-containing neurons of the cerebral cortex are also GABAergic.
Proc Natl Acad Sci.
1984;
81
6526-6530
- 31
Javanmard M, Shlik J, Kennedy S H, Vaccarino F J, Houle S, Bradwejn J.
Neuroanatomic correlates of CCK- 4-induced panic attacks in healthy humans: a comparison
of two time points.
Biol Psychiatry.
1999;
45
872-822
- 32
Knott V J, Lapierre Y D.
Effects of lactate-induced panic attacks on brain stem auditory evoked potentials.
Neuropsychobiology.
1986;
16
9-14
- 33
Knott V J, Bakish D, Barkley J.
Brainstem evoked potentials in panic disorder.
J Psychiatry and Neurosci.
1994;
19
301-306
- 34
Levy D, Kimhi R, Barak Y, Demmer M, Harel M, Elizur A.
Brainstem auditory evoked potentials of panic disorder pateints.
Neuropsychobiology.
1996;
33
164-167
- 35
Liebowitz M R, Gorman J M, Fyer A, Dillon D, Levitt M, Klein D F.
Possible mechanisms for lactate’s induction of panic.
Am J Psychiatry.
1986;
143
495-502
- 36
McDonald A, Pearson J.
Coexistence of GABA and peptide immunoractivity in non-pyramidal neurons of the basolateral
amygdala.
Neuroscience Lett.
1989;
100
53-58
- 37
Noble F, Roques B P.
CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.
Prog Neurobiology.
1999;
58
349-379
- 38
Papp L A, Klein D F, Martinez J, Schneier F, Cole R, Liebowitz M, Hollander E, Tyer A,
Jordan E, Gorman J.
Diagnostic and substance specificity or carbon dioxide-induced panic.
Am J Psychiatry.
1993;
150
250-257
- 39
Parnaud C, Eybalin M, Geffard M, Pujoi R.
Light and electron microscopic localization of GABA- immunostraining in efferent fibres
of the organ of Corti.
Neurosci Lett Suppl.
1986;
26
S284
- 40
Picton T, Hilliard S, Krausz H, Galambos R.
Human auditory evoked potentials. I: Evaluation of components.
Electroencephalogy Clin Neurophysio.
1974;
36
179-190
- 41
Pohl R, Yeragani V K, Balon R, Rainey J, Lycaki H, Ortiz A, Berchou R, Weinberg P.
Isoproterenol-induced panic attacks.
Biol Psychiatry.
1988;
24
891-902
- 42
Pyke R E, Greenberg H S.
Norepinephrine challenges in panic patients.
J Clin Psychopharmacol.
1986;
6
279-285
- 43 Rehfeld J F, Nielson F C. Molecular forms and regional distribution of cholecystokinin
in the central nervous system. In Bradwejn J, Vasar E (eds)
Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
- 44
Shlik J, Vasar E, Bradwejn J.
Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor
antagonists in therapy.
CNS Drugs.
1997;
8
134-152
- 45
Shlik J, Koszycki D, Bradwejn J.
Decrease in short-term memory ufnction induced by CCK-4 in healthy volunteers.
Peptides.
1998;
19
969-975
- 46
Shlik J, Zhou Y, Koszycki D, Vaccarino F J, Bradwejn J.
Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological
measures in healthy volunteers.
J Psychopharmacol.
1999;
13
385-390
- 47
Somogyi L, Hodgson A, Smith A, Nunzi M, Gorio A, Wu J.
Different populations of GABA-ergic neurons in the visual cortex and hippocampus of
CAT contain somatostalin or cholecystokinin-immunoreactive material.
J Neursci.
1984;
4
2590-2603
- 48
Thompson G, Cortez A, Lam D.
Localization of GABA immunoreactivity in the auditory brainstem of guinea pigs.
Brain Res.
1985;
339
119-122
- 49
van Megan H JGM, Westenberg H GM, den Boer J A, Haigh J RM, Traub M.
Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
Psychopharmacology.
1994;
114
449-455
- 50
van Megan H JGM, Westenberg H GM, Den Boer J A, Kahn R S.
The panic-inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients
with panic disorder.
Eur Neuropsychopharmacol.
1996;
6
187-194
- 51
Vetter D, Adams J, Mirgiaini E.
A dual efferent GABAergic projection to the rat cochlea.
Soc Neurosci Ab.
1986;
12
979
- 52
Westerberg B, Roberson J, Stach B.
A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus.
Am J Otol.
1996;
17
896-903
- 53 Yeudall L, Schopflocher D, Sussman P, Barabash W, Warneke L, Gill D, Oho W, Howarth B,
Tormanson P. Panic attack syndrome with and without agoraphobia: neuropsychological
and evoked potential correlates. In Flor- Henry P, Gruzedier J (eds) Laterality and
psychopathology Elsevier New York; 1983
- 54
Gormon J, Kent J, Sullivan G, Coplan J.
Neuroanatomical hypothesis of panic disorder, revised.
Am J Psychiatry.
2000;
157
493-505
- 55
Tsutsumi T, Akiyoshi J, Hikichi T, Kiyota A, Kohno Y, Katsurasi S, Yamamoto Y, Isogawa K,
Nagayama H.
Suppression of conditional fear by administration of CCKB receptor antisense oligodeoxynucleotide
into the lateral ventricle.
Pharmacopsychiatry.
2001;
6
232-237
Dr. Verner Knott
Royal Ottawa Hospital
1145 Carling Avenue
Ottawa, Ontario, K1Z 7K4
Canada
Phone: 613-722-6521 (ext. 6843)
Fax: 613-722-5048
Email: vknott@rohcg,on.ca